CN117797193A - Composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof - Google Patents
Composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN117797193A CN117797193A CN202311748710.8A CN202311748710A CN117797193A CN 117797193 A CN117797193 A CN 117797193A CN 202311748710 A CN202311748710 A CN 202311748710A CN 117797193 A CN117797193 A CN 117797193A
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- group
- flos chrysanthemi
- cerebrovascular diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 22
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 21
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 52
- 241000628997 Flos Species 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 8
- 206010020772 Hypertension Diseases 0.000 claims description 26
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 22
- 241000237502 Ostreidae Species 0.000 claims description 20
- 235000020636 oyster Nutrition 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000000605 extraction Methods 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 12
- 239000011812 mixed powder Substances 0.000 claims description 11
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 9
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 239000006286 aqueous extract Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 14
- 210000004185 liver Anatomy 0.000 abstract description 10
- 230000008816 organ damage Effects 0.000 abstract description 4
- 230000001094 effect on targets Effects 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 39
- 230000036772 blood pressure Effects 0.000 description 18
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 16
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 15
- 235000007516 Chrysanthemum Nutrition 0.000 description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 230000006378 damage Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 210000005084 renal tissue Anatomy 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 229910021642 ultra pure water Inorganic materials 0.000 description 8
- 239000012498 ultrapure water Substances 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- 230000001631 hypertensive effect Effects 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 4
- 206010023421 Kidney fibrosis Diseases 0.000 description 4
- 108010082739 NADPH Oxidase 2 Proteins 0.000 description 4
- 108010082699 NADPH Oxidase 4 Proteins 0.000 description 4
- 208000013901 Nephropathies and tubular disease Diseases 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000010025 steaming Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010006895 Cachexia Diseases 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000013875 Heart injury Diseases 0.000 description 3
- 102000004019 NADPH Oxidase 1 Human genes 0.000 description 3
- 108090000424 NADPH Oxidase 1 Proteins 0.000 description 3
- 102100021872 NADPH oxidase 4 Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000026500 emaciation Diseases 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000007103 stamina Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 230000010024 tubular injury Effects 0.000 description 3
- 208000037978 tubular injury Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 description 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 2
- 235000017784 Mespilus germanica Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000182216 Mimusops elengi Species 0.000 description 2
- 235000000560 Mimusops elengi Nutrition 0.000 description 2
- 235000007837 Vangueria infausta Nutrition 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003683 cardiac damage Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
- 229960002582 perindopril Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000233788 Arecaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 244000036905 Benincasa cerifera Species 0.000 description 1
- 235000011274 Benincasa cerifera Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 241000241550 Cyathula Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 1
- 241001633680 Polygonatum odoratum Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000223 Solitary Kidney Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000316342 Taxillus Species 0.000 description 1
- 241000270708 Testudinidae Species 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229940089639 cornsilk Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000003246 kidney medulla Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 108010087908 mouse alpha-smooth muscle actin Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000001231 zea mays silk Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof, and relates to the field of traditional Chinese medicine compositions, wherein the composition comprises the following components: flos Chrysanthemi, concha Ostreae and semen Cassiae. Compared with the traditional Chinese medicine composition with the same kind of functions in the prior art, which has the problems of complex components and numerous medicines, the composition of the invention has the advantages of only three traditional Chinese medicines, special liver channel and equivalent curative effect, certain curative effect on target organ damage caused by cardiovascular and cerebrovascular diseases, and cost saving.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine compositions, in particular to a composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof.
Background
The broad sense of cardiovascular and cerebrovascular diseases is a group of circulatory system diseases mainly comprising heart and vascular diseases, pulmonary circulatory diseases and cerebrovascular diseases, wherein the circulatory diseases are most serious in hypertension, cerebral apoplexy and coronary heart disease. Research shows that the etiology of cardiovascular and cerebrovascular diseases mainly has four aspects: (1) vascular factors such as atherosclerosis, hypertensive arteriole arteriosclerosis, arteritis, etc.; (2) hemodynamic factors such as hypertension; (3) blood rheology abnormality such as hyperlipidemia and diabetes; (4) leukemia, anemia, thrombocytosis, etc. At present, the treatment of cardiovascular and cerebrovascular diseases is mainly drug treatment except proper exercise, surgical treatment and rehabilitation treatment.
In the case of hypertension, it is understood that the increase in arterial systolic pressure and/or diastolic pressure in a resting state is often accompanied by functional or organic changes in organs such as heart, brain, kidney, retina, etc., and is classified into primary hypertension and secondary hypertension. The occurrence of hypertension is related to genetic factors, and may be due to dysfunction of the higher neural center in regulating blood pressure caused by factors such as the environment, diet, and medicines. The clinical symptoms of hypertension are dizziness, headache, mental symptoms, nerve symptoms and the like. At present, the method for preventing or treating hypertension not only has reasonable diet and avoids cold stimulation, but also has the function of conditioning and treating by using antihypertensive drugs. The traditional Chinese medicine is widely applied to the treatment of hypertension due to the advantages of wide sources of raw materials, systematic treatment, small side effects and the like.
For example books: yang Zengliang, xie Haizhou Miaofang [ M ], beijing: the formula can treat hypertension and arteriosclerosis, and mainly treats liver yang hyperactivity or yang hyperactivity fire, and is mainly used for purging excess. Book: gao Jiandong, bai Zhijun, applied to the combination of traditional Chinese and Western medicine with nephrology [ M ], jinan: in the diagnosis and treatment of hypertension kidney injury by traditional Chinese medicine, 2016:135, the prescription of yin deficiency and yang hyperactivity is modified on the basis of liver-fire-calming soup, and is prepared from 30g of rehmannia root, 12g of pulp of dogwood fruit, 15g of radix asparagi, 15g of dwarf lilyturf tuber, 30g of Chinese yam, 30g of poria cocos, 12g of rhizoma alismatis, 30g of radix scrophulariae, 12g of tortoise plastron, 30g of calcined oyster, 15g of medicinal cyathula root, 12g of Chinese taxillus twig, 10g of medlar, 15g of chrysanthemum morifolium, and the prescription is mainly used for treating symptoms such as headache dizziness, light weight of the head and foot, vexation and insomnia, and heat of the palms and soles.
Also as in patent CN113633727A, a traditional Chinese medicine composition for treating hypertension comprises the following components in parts by weight: 10-15 parts of oyster; 10-15 parts of kudzuvine root; 5-10 parts of medlar; 15-20 parts of wax gourd; 5-10 parts of hawthorn; 3-7 parts of semen cassiae; 5-10 parts of chrysanthemum; 10-15 parts of Chinese yam; 10-15 parts of Chinese date; 3-6 parts of peppermint; 2-6 parts of corn silk; 4-9 parts of rhizoma polygonati; 1-4 parts of dried orange peel; 3-7 parts of malt extract; 5-10 parts of edible starch; 5-10 parts of xylitol; 1-2 parts of magnesium stearate; 1-2 parts of ionized calcium, and the traditional Chinese medicine composition has the effects of activating blood circulation to dissipate blood stasis, softening blood vessels, regulating qi to alleviate pain, calming liver to replace yang, reducing blood pressure and quenching thirst and enhancing human immunity; the traditional Chinese medicine composition provided by the invention has obvious antihypertensive effect, and is safe and free of side effects.
However, the above components are complex, the medicines are numerous and the cost is high, so it is necessary to find a composition for treating cardiovascular and cerebrovascular diseases with excellent treatment effect and simple components and a preparation method thereof.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides a composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof, the composition has simple administration, equivalent curative effect and certain curative effect on target organ damage caused by cardiovascular and cerebrovascular diseases and saves cost.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
the invention provides a composition, which consists of the following components: flos Chrysanthemi, concha Ostreae and semen Cassiae.
Further, the chrysanthemum comprises one or more of chrysanthemum morifolium, chrysanthemum morifolium and chrysanthemum, and the oyster comprises calcined oyster and/or raw oyster.
Preferably, the chrysanthemum is Hangzhou white chrysanthemum and the oyster is calcined oyster.
Further, the composition comprises the following components in parts by weight: 8-12 parts of chrysanthemum morifolium, 12-18 parts of calcined oyster and 8-12 parts of cassia seed.
Preferably, the composition comprises the following components in parts by weight: 10 parts of chrysanthemum morifolium, 15 parts of calcined oyster and 10 parts of cassia seed.
Further, the invention also provides a preparation method of the composition, which comprises the following steps:
(1) Respectively pulverizing flos Chrysanthemi, concha Ostreae and semen Cassiae, sieving, and mixing to obtain mixed powder;
(2) Soaking the mixed powder in water, decocting for the first time, and centrifuging to obtain supernatant and residue;
(3) Adding water into the residues obtained in the step (2) for carrying out secondary decoction extraction and centrifugation to obtain supernatant;
(4) Mixing the supernatant obtained in the step (2) and the supernatant obtained in the step (3) to obtain an aqueous extract;
(5) Concentrating the water extract, and filtering.
Further, the adding volume of the water in the step (2) is 5-20 times of that of the mixed powder; the adding volume of the water in the step (3) is 5-20 times of the adding volume of the dregs.
Preferably, the water is added in step (2) in a volume 10 times the volume of the mixed powder; the adding volume of the water in the step (3) is 8 times of the adding volume of the medicine residues.
Further, the soaking time in the step (2) is more than or equal to 30 minutes, the boiling time of the first decoction and extraction is 0.5-2 hours, and the boiling time of the second decoction and extraction is 0.5-2 hours.
Preferably, the soaking time in the step (2) is 30 minutes, the boiling time of the first decoction is 2 hours, and the boiling time of the second decoction is 2 hours.
Further, the composition or the composition prepared by the preparation method can be applied to the preparation of medicaments for treating cardiovascular and cerebrovascular diseases.
Further, the cardiovascular and cerebrovascular diseases comprise hypertension, cerebral apoplexy, atherosclerosis, angina pectoris, myocardial infarction or coronary heart disease.
Preferably, the cardiovascular and cerebrovascular diseases are hypertension.
Further, the medicament also comprises pharmaceutically acceptable auxiliary materials.
In some embodiments, the adjuvant includes one or more of a diluent, a binder, a disintegrant, a lubricant, and a preservative.
Further, the dosage form of the medicament comprises tablets, granules, capsules, paste, powder or pills.
The invention has the technical effects that:
1. the composition takes chrysanthemum morifolium ramat as a monarch drug and is one of eight medicinal materials in Zhejiang. The Chinese pharmacopoeia records that the Hangzhou white chrysanthemum is slightly cold in nature, bitter in taste, sweet in flavor, enters lung and liver meridian, has the effects of dispelling wind and clearing heat, suppressing hyperactive liver and improving eyesight, and clearing heat and detoxicating, and is used for wind-heat type common cold, headache and dizziness, conjunctival congestion and swelling and pain, eye dizziness and sore and carbuncle swelling and toxin. The Shennong Ben Cao Jing (Shennong's herbal medicine) records that Hangzhou white chrysanthemum is mainly used for treating dizziness, swelling and pain, eye loss, skin death and arthralgia due to wind-dampness, and is taken for a long time to promote qi circulation, lighten body and endure fatigue and prolong life. Semen cassiae is taken as ministerial medicine, sweet, bitter and salty in taste, slightly cold in nature, enters liver, kidney and large intestine channels, has the effects of clearing liver and improving vision, and relaxing bowel, and is classified as superior in the earliest Shennong herbal channel, and is called as being capable of treating various eye diseases, nourishing vital essence for long time and reducing weight. Calcined oyster is taken as an adjuvant drug, is slightly cold in nature, salty in taste, enters liver, gall bladder and kidney meridians, and has the effects of relieving uneasiness, suppressing yang hyperactivity, tonifying yin, softening hardness and resolving hard mass. In addition, with the principal deficiency, the calcined oyster is considered to be "treating deficiency and new diseases with sudden deficiency, body fluids with unsecured, spontaneous sweating, even night lying, emaciation due to deficiency, stamina and emaciation due to emaciation, stamina due to stamina, shortness of breath and restlessness. The medicine is used as an adjuvant, and the medicines are used for entering liver meridian in the adjuvant, and the medicines are used for tonifying deficiency in the adjuvant.
2. The traditional hypertension-induced mouse model is subjected to unilateral kidney excision, doca particles are implanted subcutaneously to induce the hypertension model, and the traditional Chinese medicine composition has obvious inhibition effect on hypertension rise of a model group through 28-day administration study. At the same time, the composition can also relieve morphological damage of kidney and heart tissues and relieve kidney fibrosis. The composition is based on the theory of monarch, minister, assistant and guide of traditional Chinese medicine, and the components are mutually matched, so that an excellent using effect is achieved.
3. Compared with the traditional Chinese medicine composition with the same kind of functions in the prior art, which has the problems of complex components and numerous medicines, the composition of the invention has the advantages of only three traditional Chinese medicines, special liver channel and equivalent curative effect, certain curative effect on target organ damage caused by cardiovascular and cerebrovascular diseases, and cost saving.
Drawings
FIG. 1 shows the change in Systolic Blood Pressure (SBP) of mice in each group;
FIG. 2 shows the Mean Blood Pressure (MBP) change in each group of mice;
FIG. 3 shows the change in Diastolic Blood Pressure (DBP) of mice in each group;
FIG. 4 shows Heart Rate (HR) variation in mice in each group;
FIG. 5 is a graph showing cardiac index (Heart index) profile for each group of mice;
FIG. 6 shows the Kidney index (Kidney index) profile for each group of mice;
FIG. 7 is a graph showing the 12h urine Volume (12 h urine Volume) of each group of mice;
FIG. 8 is a graph showing urea nitrogen (Serum BUN) status for each group of mice;
FIG. 9 shows Serum creatinine (Serum creatinine) for each group of mice;
FIG. 10 shows the results of the histological damage of glomeruli (20 μm) in each group, wherein (a) is a blank group, (b) is a model group, (c) is a high dose group of example 1, (d) is a low dose group of example 1, and (e) is a positive control group;
FIG. 11 is a glomerular injury index profile;
FIG. 12 shows the histological damage of renal cortex (50 μm) in each group, wherein (a) is a blank group, (b) is a model group, (c) is a high dose group of example 1, (d) is a low dose group of example 1, and (e) is a positive control group;
FIG. 13 shows the results of the histological lesions of the renal medulla (50 μm) of the respective groups, wherein (a) is a blank group, (b) is a model group, (c) is a high dose group of example 1, (d) is a low dose group of example 1, and (e) is a positive control group;
FIG. 14 is a graph showing the index of tubular injury;
FIG. 15 shows the histological damage of the hearts (50 μm) of each group, wherein (a) is a blank group, (b) is a model group, (c) is a high dose group of example 1, (d) is a low dose group of example 1, and (e) is a positive control group;
FIG. 16 is a graph showing cardiac injury index profile;
FIG. 17 shows the deposition of collagen fibers in glomeruli (20 μm) of each group, wherein (a) is a blank group, (b) is a model group, (c) is a high dose group of example 1, (d) is a low dose group of example 1, and (e) is a positive control group;
FIG. 18 shows collagen fiber deposition in each of the renal cortex (50 μm) groups, wherein (a) is a blank group, (b) is a model group, (c) is a high dose group of example 1, (d) is a low dose group of example 1, and (e) is a positive control group;
FIG. 19 shows the expression levels of TGF-beta messenger RNA in mice of each group;
FIG. 20 shows the expression levels of mouse alpha-SMA messenger RNA for each group;
FIG. 21 shows the expression level of Collagen I messenger RNA in each group of mice;
FIG. 22 shows the expression levels of the Collagen III messenger RNA in each group of mice;
FIG. 23 shows the levels of NOX1 mRNA expression in mice of each group;
FIG. 24 is a graph showing the levels of NOX2 mRNA expression in mice of each group;
FIG. 25 shows the expression levels of NOX4 mRNA in mice of each group;
in each of the above figures, #p <0.05, #p <0.01, compared to the blank; p <0.05, < P <0.01 compared to model group.
Detailed Description
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention.
Before the embodiments of the invention are explained in further detail, it is to be understood that the invention is not limited in its scope to the particular embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It should be noted that the raw materials used in the present invention are all common commercial products, and therefore the sources thereof are not particularly limited.
Example 1
A composition for treating cardiovascular and cerebrovascular diseases comprises the following components in parts by weight: 10g of Hangzhou white chrysanthemum, 15g of calcined oyster and 10g of cassia seed.
The preparation method of the traditional Chinese medicine compound comprises the following steps:
(1) Pulverizing the above materials into fine powder respectively, sieving with No. 7 sieve, and mixing;
(2) Adding 10 times of volume of ultrapure water into the uniformly mixed powder for first decoction extraction, soaking for 30 minutes in advance, boiling for 2 hours when the medicine completely absorbs water, centrifuging, and taking the supernatant;
(3) Adding 8 times of volume of ultrapure water into the residues after the first extraction for the second decoction and extraction for 2 hours, centrifuging, and collecting the supernatant;
(4) Mixing the supernatants extracted from the two steps to obtain an aqueous extract;
(5) Rotary steaming the water extract, concentrating the filtrate at low temperature to crude drug 0.46g/ml, filtering with a filter membrane, packaging the liquid medicine into 15ml centrifuge tube, and storing at-80deg.C.
Example 2
A composition for treating cardiovascular and cerebrovascular diseases comprises the following components in parts by weight: 8g of Hangzhou white chrysanthemum, 12g of calcined oyster and 8g of cassia seed.
The preparation method of the traditional Chinese medicine compound comprises the following steps:
(1) Pulverizing the above materials into fine powder respectively, sieving with No. 7 sieve, and mixing;
(2) Adding 5 times of ultrapure water into the uniformly mixed powder for first decoction extraction, soaking for 30 minutes in advance, boiling for 0.5 hour when the medicine completely absorbs water, centrifuging, and collecting supernatant;
(3) Adding 5 times of volume of ultrapure water into the residues after the first extraction for the second decoction extraction for 0.5h, centrifuging, and collecting the supernatant;
(4) Mixing the supernatants extracted from the two steps to obtain an aqueous extract;
(5) Rotary steaming the water extract, concentrating the filtrate at low temperature to crude drug 0.46g/ml, filtering with a filter membrane, packaging the liquid medicine into 15ml centrifuge tube, and storing at-80deg.C.
Example 3
A composition for treating cardiovascular and cerebrovascular diseases comprises the following components in parts by weight: 12g of Hangzhou white chrysanthemum, 18g of calcined oyster and 12g of cassia seed.
The preparation method of the traditional Chinese medicine compound comprises the following steps:
(1) Pulverizing the above materials into fine powder respectively, sieving with No. 7 sieve, and mixing;
(2) Adding 20 times of ultra-pure water into the mixed powder for first decoction extraction, soaking for 30 minutes in advance, boiling for 2 hours when the medicine completely absorbs water, centrifuging, and collecting the supernatant;
(3) Adding 20 times of ultrapure water into the residues after the first extraction for the second decoction extraction for 2 hours, centrifuging, and collecting the supernatant;
(4) Mixing the supernatants extracted from the two steps to obtain an aqueous extract;
(5) Rotary steaming the water extract, concentrating the filtrate at low temperature to crude drug 0.46g/ml, filtering with a filter membrane, packaging the liquid medicine into 15ml centrifuge tube, and storing at-80deg.C.
Example 4
A composition for treating cardiovascular and cerebrovascular diseases comprises the following components in parts by weight: 10g of chrysanthemum, 15g of raw oyster and 10g of cassia seed.
The preparation method of the traditional Chinese medicine compound comprises the following steps:
(1) Pulverizing the above materials into fine powder respectively, sieving with No. 7 sieve, and mixing;
(2) Adding 10 times of volume of ultrapure water into the uniformly mixed powder for first decoction extraction, soaking for 30 minutes in advance, boiling for 2 hours when the medicine completely absorbs water, centrifuging, and taking the supernatant;
(3) Adding 8 times of volume of ultrapure water into the residues after the first extraction for the second decoction and extraction for 2 hours, centrifuging, and collecting the supernatant;
(4) Mixing the supernatants extracted from the two steps to obtain an aqueous extract;
(5) Rotary steaming the water extract, concentrating the filtrate at low temperature to crude drug 0.46g/ml, filtering with a filter membrane, packaging the liquid medicine into 15ml centrifuge tube, and storing at-80deg.C.
Comparative example 1
The difference from example 1 is only Hangzhou white chrysanthemum (preparation method is the same as in example 1, and raw materials are added according to the composition condition).
Comparative example 2
The only difference from example 1 is that only calcined oyster was used (the preparation method is the same as in example 1, and the addition of raw materials was adjusted according to the composition conditions).
Comparative example 3
The only difference from example 1 is that only semen Cassiae was used (the preparation method is the same as in example 1, and the raw materials are added according to the composition).
Comparative example 4
The composition consists of the following components in parts by weight: 10g of Hangzhou white chrysanthemum, 15g of calcined oyster, 10g of cassia seed and 10g of fragrant solomonseal rhizome.
That is, the difference from example 1 is that 10g of Polygonatum odoratum was further contained in the composition (the preparation method was the same as that of example 1, and the addition of the raw materials was adjusted according to the composition conditions).
Comparative example 5
The composition consists of the following components in parts by weight: hangzhou white chrysanthemum 14g, calcined oyster 7g and cassia seed 14g (the preparation method is the same as that of example 1, and the raw materials are added according to the situation of the composition).
1. Test study on composition for relieving DOCA/Salt-induced blood pressure elevation in the invention
(1) After one week of adaptive rearing of all experimental C57 mice, a single kidney extirpation was performed.
(2) After one week of surgical recovery, the mice were numbered with numbers, randomly decimated to groups the numbers, as follows: blank (Ctrl, n=7), model (DOCA/Salt, n=7), DOCA/Salt plus example 1 low dose group of the composition of example 1 (2.3 g/kg/d, n=7), DOCA/Salt plus example 1 high dose group of the composition of example 1 (4.6 g/kg/d, n=7), DOCA/Salt plus examples 2-4, comparative examples 1-5 high dose group (4.6 g/kg/d, each group n=7), DOCA/Salt plus positive drug Perindopril (Perindopril, 2mg/kg/d, n=7), respectively, where n is the number of mice in each group.
Regarding molding: classical hypertension models were induced with DOCA/Salt and each example group was given a traditional Chinese medicine composition for intervention. The blood pressure is measured by adopting a tail sleeve method, and the blood pressure of the DOCA/Salt model group is obviously increased in the whole experimental period, which shows that the modeling is successful.
(3) After collecting the basic blood pressure, the model group and each administration group are respectively buried into DOCA slow release capsules (40 mg/mice) subcutaneously, and the control group performs false operation at the corresponding position. After the operation, the model and the drinking water of each administration group are changed into 1% saline.
(4) The stomach irrigation administration is started after the operation is finished, according to the clinical dosage of the traditional Chinese medicine composition, the standard weight is 70kg, the conversion coefficient is 9.1, the corresponding administration dosage of the mice is calculated to be 4.6g/kg/d, and the mice are used as high-dosage groups, and the low dosage is half of the high-dosage groups. Positive dosage is referred to the literature. The administration volume was maintained for 4 weeks at the time of gastric lavage according to the standard of 0.1ml/10g based on the body weight of the mice.
(5) All mice were monitored for adaptation three consecutive days prior to the formal collection of data, except for the basal blood pressure, to reduce the stress response of the mice when the data were formally collected. Mice were monitored for blood pressure every 2-3 days for 4 weeks. When blood pressure is measured, the surrounding environment is kept quiet, under the condition that animals are quiet and the blood pressure real-time monitoring waveform is stable when data are collected, the systolic pressure (SBP), the diastolic pressure (DBP), the average blood pressure (MBP) and the Heart Rate (HR) are recorded, and the data in the stable state are collected for 5 times for each animal, wherein the average value is the data of the blood pressure monitoring.
(6) After the end of the experiment, the mouse samples were collected.
As shown in fig. 1-3, the high and low doses of example 1 were used to intervene simultaneously with the treatment of the model group, and the high and low doses of example 1 delayed the elevation of blood pressure (SBP, MBP, DBP) from day 6 (P <0.05, P < 0.01) compared to the model group. The positive control group had a slow tendency to increase in blood pressure, and was maintained at substantially normal blood pressure levels. As shown in fig. 4, the heart rate of the traditional Chinese medicine composition of example 1 was significantly reduced (P < 0.01) in the model group at week 4 compared to the model group. The result shows that the traditional Chinese medicine composition has an inhibiting effect on DOCA/Salt-induced blood pressure increase and a heart rate reducing effect.
2. Composition of the invention for the test and study of renal function protection
After the experiment is finished for 4 weeks, taking tissue specimens of the heart and the kidney of the mice, comparing and calculating the tissue specimens with the body mass to obtain heart indexes and kidney indexes (as shown in figures 5-6), wherein compared with a blank control group, the heart and kidney indexes of a model group are obviously increased (P < 0.01), and after the administration of the high-dose group in the embodiment 1 of the invention, the increase of the heart and kidney indexes is obviously reduced (P < 0.05); after loading mice into a metabolic cage to collect 12h urine, the 12h urine is quantified, and as can be seen from fig. 7, the urine volume of the model group is significantly increased (P < 0.01) compared with the control group, and the high dosage of the composition of the embodiment 1 of the invention improves the trend (P < 0.05); serum creatinine and urea nitrogen levels are important indicators for assessing impaired renal function, as shown in fig. 8-9, the serum creatinine (Cr) and urea nitrogen (BUN) levels were significantly elevated in the model group compared to the placebo group, indicating impaired hypertensive renal function, while the compositions of the examples of the invention significantly reduced elevated serum creatinine and urea nitrogen levels in the model group after treatment. The above results show that the composition of the examples of the present invention can protect kidney function, and compared with the composition of each comparative example, there is a significant difference in some indexes from the examples, and the effect of protecting kidney function is relatively small.
The heart index, kidney index, 12h urine volume and serum creatinine of each group of mice in the invention are shown in the following table:
TABLE 1 cardiac index, renal index, 12h urine volume, urea Nitrogen and serum creatinine status for mice of each group in the invention
(note: compared to the blank group, #P<0.05，##P<0.01; compared with model group, P<0.05，**P<0.01; in contrast to the high dose group of example 1, ▲ P<0.05， ▲▲ P<0.01。)
3. investigation of kidney and heart histomorphology injury test of hypertension-relieving mice by composition of the invention
Kidney tissue HE staining as shown in fig. 10, 12 and 13, glomerular boundary was unclear, basement membrane was increased, nucleus was increased, glomerular network structure was not apparent, glomerular injury and tubular interstitial injury were increased in DOCA/Salt treated mice kidney tissue; as shown in fig. 11 and 14, the damage condition of kidney tissue is obviously reduced (P < 0.01) after the high and low doses of the example 1 are applied; similar trends also appear in the cardiac histomorphology results, namely, the model group shows pathological manifestations such as myocardial cell hypertrophy, gap widening, looseness, myocardial fiber arrangement disorder and the like (fig. 15), the cardiac damage score is obviously increased, the abnormal cardiac histomorphology indexes are obvious after the composition of the embodiment of the invention intervenes, and the cardiac damage is reduced (fig. 16); the results show that the composition provided by the embodiment of the invention can relieve morphological damage of kidney and heart tissues. In contrast, there was a significant difference in some of the indices between the compositions of each comparative example and the examples, and the effect on alleviating the morphological damage of kidney and heart tissues was relatively small.
The glomerular injury index and the tubular injury index and the cardiac injury index of each group of mice in the invention are shown in the following table:
TABLE 2 glomerular injury index, tubular injury index and cardiac injury index of mice of each group of the present invention
(note: compared to the blank group, #P<0.05，##P<0.01; compared with model group, P<0.05，**P<0.01; in contrast to the high dose group of example 1, ▲ P<0.05， ▲▲ P<0.01。)
4. experimental study on reducing kidney fibrosis of hypertensive mice by composition in the invention
The results of observing collagen fiber deposition of kidney cortex and medulla in mice by using masson staining are shown in fig. 17, and the composition of example 1 of the present invention significantly reduced collagen deposition caused by DOCA/Salt after administration.
To investigate the specific mechanism of action of the composition of the invention on kidney fibrosis, mRNA expression of fibrosis markers alpha-SMA, collagen I, collagen III and mRNA expression of fibrosis regulatory key mediators TGF-beta in the kidney were examined, and as a result, it was found (see FIGS. 18-22 for details) that the fibrosis marker level of DOCA/Salt model group was significantly increased, while the composition of example 1 of the invention significantly reduced expression of fibrosis markers alpha-SMA, collagen I, collagen III in the kidney of hypertensive mice, while inhibiting expression of fibrosis regulatory key mediators TGF-beta. The results show that the composition provided by the invention can relieve kidney fibrosis of hypertensive mice.
5. Expression test study of composition for reducing NOXs in kidney tissue of hypertensive mice
Further analysis of the expression of the NOX1, NOX2, NOX4 genes in the kidneys showed (see figures 23-25 for details) that the DOCA/Salt model group NOX1, NOX2, NOX4 expression was significantly increased, the high dose group of example 1 of the present invention significantly reduced NOX2 expression in the kidney tissue (P < 0.05), whereas NOX4 had a decreasing trend, but no statistical significance.
The experimental result shows that the traditional Chinese medicine composition can delay the blood pressure rise caused by DOCA/Salt hypertension mice, improve the protection effect of kidney and heart tissue damage caused by hypertension, and is expected to be used as a potential therapeutic drug for hypertension target organ damage.
Finally, it should be noted that the above description is only for illustrating the technical solution of the present invention, and not for limiting the scope of the present invention, and that the simple modification and equivalent substitution of the technical solution of the present invention can be made by those skilled in the art without departing from the spirit and scope of the technical solution of the present invention.
Claims (11)
1. A composition characterized by: consists of the following components: flos Chrysanthemi, concha Ostreae and semen Cassiae.
2. The composition of claim 1, wherein: the flos Chrysanthemi comprises one or more of flos Chrysanthemi, embryo flos Chrysanthemi and flos Chrysanthemi, and the Concha Ostreae comprises calcined Concha Ostreae and/or Concha Ostreae.
3. The composition of claim 2, wherein: the coating comprises the following components in parts by weight: 8-12 parts of chrysanthemum morifolium, 12-18 parts of calcined oyster and 8-12 parts of cassia seed.
4. A composition according to claim 3, characterized in that: the coating comprises the following components in parts by weight: 10 parts of chrysanthemum morifolium, 15 parts of calcined oyster and 10 parts of cassia seed.
5. A method of preparing a composition according to any one of claims 1 to 4, wherein: the method comprises the following steps:
(1) Respectively pulverizing flos Chrysanthemi, concha Ostreae and semen Cassiae, sieving, and mixing to obtain mixed powder;
(2) Soaking the mixed powder in water, decocting for the first time, and centrifuging to obtain supernatant and residue;
(3) Adding water into the residues obtained in the step (2) for carrying out secondary decoction extraction and centrifugation to obtain supernatant;
(4) Mixing the supernatant obtained in the step (2) and the supernatant obtained in the step (3) to obtain an aqueous extract;
(5) Concentrating the water extract, and filtering.
6. The method of manufacturing according to claim 5, wherein: the adding volume of the water in the step (2) is 5-20 times of that of the mixed powder; the adding volume of the water in the step (3) is 5-20 times of the adding volume of the dregs.
7. The method of manufacturing according to claim 5, wherein: the soaking time in the step (2) is more than or equal to 30 minutes, the boiling time of the first decoction and extraction is 0.5-2 hours, and the boiling time of the second decoction and extraction is 0.5-2 hours.
8. Use of a composition according to any one of claims 1 to 4 or a composition obtainable by a process according to any one of claims 5 to 7 in the manufacture of a medicament for the treatment of cardiovascular and cerebrovascular diseases.
9. The use according to claim 8, characterized in that: the cardiovascular and cerebrovascular diseases comprise hypertension, cerebral apoplexy, atherosclerosis, angina pectoris, myocardial infarction or coronary heart disease.
10. The use according to claim 8, characterized in that: the medicine also comprises pharmaceutically acceptable auxiliary materials.
11. The use according to claim 8, characterized in that: the dosage forms of the medicine comprise tablets, granules, capsules, ointment, powder or pills.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311748710.8A CN117797193A (en) | 2023-12-18 | 2023-12-18 | Composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311748710.8A CN117797193A (en) | 2023-12-18 | 2023-12-18 | Composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117797193A true CN117797193A (en) | 2024-04-02 |
Family
ID=90421301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311748710.8A Pending CN117797193A (en) | 2023-12-18 | 2023-12-18 | Composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117797193A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199623A (en) * | 2006-12-16 | 2008-06-18 | 石茂光 | Preparing method for treating hypertension drug slow controlled-release preparation |
| CN101884662A (en) * | 2009-05-15 | 2010-11-17 | 天津太平洋制药有限公司 | Food therapy preparation for preventing and treating hypertension based on theories of preventive treatment of disease and medicine food homology |
| CN106942327A (en) * | 2017-03-30 | 2017-07-14 | 亳州学院 | A kind of feature biscuit containing Bo chrysanthemum and cassia seed |
| CN109010808A (en) * | 2018-10-19 | 2018-12-18 | 吉林省恒实传食品科技发展有限公司 | A kind of health care's food formula and preparation method thereof of reducing blood lipid prevention cardiovascular and cerebrovascular disease |
-
2023
- 2023-12-18 CN CN202311748710.8A patent/CN117797193A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199623A (en) * | 2006-12-16 | 2008-06-18 | 石茂光 | Preparing method for treating hypertension drug slow controlled-release preparation |
| CN101884662A (en) * | 2009-05-15 | 2010-11-17 | 天津太平洋制药有限公司 | Food therapy preparation for preventing and treating hypertension based on theories of preventive treatment of disease and medicine food homology |
| CN106942327A (en) * | 2017-03-30 | 2017-07-14 | 亳州学院 | A kind of feature biscuit containing Bo chrysanthemum and cassia seed |
| CN109010808A (en) * | 2018-10-19 | 2018-12-18 | 吉林省恒实传食品科技发展有限公司 | A kind of health care's food formula and preparation method thereof of reducing blood lipid prevention cardiovascular and cerebrovascular disease |
Non-Patent Citations (2)
| Title |
|---|
| 唐夏莉;陈素红;吕圭源;苏洁;佟海宁;占阮娟;张燕坪;: "复方菊明提取物对高血压伴高尿酸血症模型大鼠尿酸的影响", 浙江中医药大学学报, vol. 36, no. 12, 15 December 2012 (2012-12-15), pages 1321 - 1324 * |
| 王雨航, 等: "990降压颗粒治疗原发性高血压病临床研究", 中国中医药信息杂志, vol. 18, no. 05, 15 May 2011 (2011-05-15), pages 64 - 65 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012027882A1 (en) | Pharmaceutical composition for treating insomnia and preparation method thereof | |
| RU2426553C2 (en) | Traditional chinese medications for treatment of depression, their composition, method of preparation and treatment | |
| CN105079577A (en) | Traditional Chinese medicine composition for treating hypertension and preparing method thereof | |
| US20030143289A1 (en) | Herbal composition PHY828 and its use | |
| CN117797193A (en) | Composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN107812115A (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN103585495B (en) | Capsule for treating diabetic kidney damage | |
| CN107648335B (en) | Traditional Chinese medicine composition for regulating atherosclerosis autophagy and apoptosis and preparation method thereof | |
| CN103768349B (en) | Application in preparation treatment cerebrovascular and relevant disease medicine for the four taste Fructus cinnamomi camphorae preparations | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN105664133A (en) | Oral solid preparation for treating hypertension and preparing method thereof | |
| CN110522798A (en) | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease | |
| CN114848724B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN103520538B (en) | A kind ofly treat the pharmaceutical composition that diabetes cause kidney damage | |
| CN108969581B (en) | Traditional Chinese medicine composition for treating diabetic retinopathy | |
| CN116999533B (en) | Heart-nourishing and pulse-activating granule, preparation method thereof and application thereof in antidepressant product | |
| CN103495065B (en) | Enema particles for treating diabetic nephropathy and preparation method for enema particles | |
| CN113521131B (en) | Traditional Chinese medicine composition for ischemic cardiomyopathy and application thereof | |
| CN108175818B (en) | Traditional Chinese medicine composition for treating glaucoma and preparation method and application thereof | |
| CN106074736A (en) | A kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof | |
| CN105796684B (en) | Composition, traditional Chinese medicine composition and application thereof | |
| CN107485683A (en) | A kind of Chinese and Western medicine compound granule for preventing and treating after cardiac surgery complication | |
| CN103520414B (en) | Chinese medicament for treating bronchial asthma | |
| CN114042099A (en) | anti-Parkinson-dementia syndrome cyclolepine pair and preparation method thereof | |
| CN118340839A (en) | Heart-nourishing and vein-invigorating composition, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |